No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".
Sign up to see all 5.
Sign up to see all 5.
No insider has filed a notice of proposed sale (Form 144) for XOMA Royalty Corp in the last 12 months.
| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
BI
BVF Inc/il
13D · 0.0%
|
7.6M | 60.55% | +5.0M (+193.1%) | ≤2021 | 8.3% | |
|
Shares held by quarter
Peak holding7.6M (Q2'26)
Change over 8 quarters+4.0M
Share of the company60.550%
Disclosed stake13D · 0.0%
|
||||||
|
MS
Morgan Stanley
|
1.7M | 13.53% | −5.0K (−0.3%) | ≤2021 | 0.0% | |
|
Shares held by quarter
Peak holding1.7M (Q4'25)
Change over 8 quarters+1.5M
Share of the company13.530%
|
||||||
28 more super investors behind a free account
See every manager holding XOMA Royalty Corp, how their position has changed, and how long they've held it.
Sign up free| Fund | Position value | Shares | % of company | % of the fund | As of |
|---|---|---|---|---|---|
|
FC
Fidelity Contrafund
|
$40.1M | 944.1K | 7.53% | 0.02% | June 30, 2026 |
|
VT
Vanguard Index Funds
|
$16.2M | 380.6K | 3.03% | 0.00% | June 30, 2026 |
23 more funds behind a free account
See every fund holding XOMA Royalty Corp and how much of the fund the position is.
Sign up free| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
LP
Ligand Pharmaceuticals Incorporated
5%+ holder
13D · 47.0%
|
8.1M | 64.29% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
Loading...